Ebola vax protects monkeys from three strains; Novavax names Mark Thornton new CMO;

Vaccine Research

Nancy J. Sullivan of the Vaccine Research Center at the U.S. National Institute of Allergy and Infectious Diseases led a team that developed a new ebola vaccine which successfully protected monkeys from three strains of the deadly virus. Story

Novavax announced today the appointment of Mark O. Thornton, M.D., M.P.H., Ph.D., as the company's senior vice president, development and chief medical officer. Before joining Novavax, Dr. Thornton was a medical officer in the U.S. Navy and the FDA's immunology and infectious diseases branch and division of therapeutic biologic oncology products, chief medical officer of ZioPharm Oncology, managing director of clinical and regulatory affairs at Angiotech Pharmaceuticals and, most recently, senior vice president of product development at GenVec. Release

Australian officials are funding new research work on a horse vaccine to guard against the Hendra virus, which can kill both horses and the humans they come in contact with. Report

Nabi is conducting a late-stage trial of NicVAX at 25 sites around the country. Story

H1N1

A new study underscores the dangers pregnant women face when they are exposed to swine flu. Story

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.